The World Health Organization has issued its first guideline on the use of GLP-1 therapies, such as Ozempic, to treat obesity, a chronic disease affecting more than 1 billion people worldwide and projected to double by 2030.

A McGill University expert is available to comment:

Michael Tsoukas, MD, is an Associate Professor in the Division of Endocrinology, Co-Director of the Metabolic Centre of Excellence at the McGill University Health Centre (MUHC) and an Investigator at the Research Institute of the MUHC. He can discuss how GLP-1 therapies work, what the new guidelines mean for treatment access and clinical practice and emerging research on benefits beyond weight loss.

michael.tsoukas [at] mcgill.ca (English, French)